
Scandinavian ChemoTech - Growth tailwinds

Redeye provides an update on Scandinavian ChemoTech following the Q2 2025 report. Net sales came in mostly as we had foreseen, in line with the order intake announced in early July. Cost control was solid, and the company is now on the brink of reaching EBITDA breakeven. We trim our estimates for the cost base but mostly maintain our top line forecast. Our fair value range is increased slightly, with a more pronounced effect on our Bear Case, as the risk in our pessimistic scenario is reduced following the recent capital raise.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Scandinavian ChemoTech - Growth tailwinds